Pfizer Inc. (NYSE:PFE) Short Interest Update

Pfizer Inc. (NYSE:PFEGet Rating) saw a large increase in short interest in the month of May. As of May 31st, there was short interest totalling 77,200,000 shares, an increase of 33.9% from the May 15th total of 57,670,000 shares. Based on an average trading volume of 26,270,000 shares, the short-interest ratio is presently 2.9 days.

A number of research firms have recently weighed in on PFE. Wells Fargo & Company reduced their target price on shares of Pfizer from $60.00 to $55.00 in a report on Wednesday, May 4th. Barclays set a $52.00 price target on shares of Pfizer in a report on Tuesday, May 17th. SVB Leerink started coverage on shares of Pfizer in a report on Monday, May 23rd. They issued a “market perform” rating and a $55.00 price target for the company. Citigroup increased their price target on shares of Pfizer from $46.00 to $57.00 and gave the company a “neutral” rating in a report on Tuesday, April 5th. Finally, Berenberg Bank set a $50.00 price target on shares of Pfizer in a report on Friday, May 27th. Nine research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Pfizer currently has an average rating of “Buy” and an average target price of $57.26.

Shares of NYSE:PFE opened at $46.53 on Friday. The firm has a market cap of $261.07 billion, a PE ratio of 10.67, a price-to-earnings-growth ratio of 0.59 and a beta of 0.76. The firm’s 50 day simple moving average is $50.90 and its 200-day simple moving average is $52.34. Pfizer has a one year low of $38.70 and a one year high of $61.71. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.13 and a current ratio of 1.39.

Pfizer (NYSE:PFEGet Rating) last issued its earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $1.62 EPS for the quarter, missing analysts’ consensus estimates of $1.66 by ($0.04). The company had revenue of $25.66 billion for the quarter, compared to analysts’ expectations of $24.73 billion. Pfizer had a return on equity of 38.29% and a net margin of 26.97%. The business’s revenue was up 76.8% compared to the same quarter last year. During the same period last year, the business posted $0.93 earnings per share. Equities research analysts predict that Pfizer will post 6.62 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Friday, June 10th. Stockholders of record on Friday, May 13th were given a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 3.44%. The ex-dividend date was Thursday, May 12th. Pfizer’s dividend payout ratio (DPR) is presently 36.70%.

In other news, SVP Jennifer B. Damico sold 4,000 shares of Pfizer stock in a transaction that occurred on Monday, May 16th. The shares were sold at an average price of $50.50, for a total transaction of $202,000.00. Following the sale, the senior vice president now owns 15,064 shares in the company, valued at $760,732. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Jennifer B. Damico sold 4,218 shares of Pfizer stock in a transaction that occurred on Tuesday, June 7th. The shares were sold at an average price of $53.96, for a total transaction of $227,603.28. Following the sale, the senior vice president now owns 10,846 shares in the company, valued at approximately $585,250.16. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 41,126 shares of company stock worth $2,075,003. 0.05% of the stock is owned by company insiders.

Several large investors have recently modified their holdings of PFE. Worth Asset Management LLC purchased a new position in Pfizer during the first quarter valued at approximately $29,000. Econ Financial Services Corp purchased a new position in Pfizer in the fourth quarter worth $31,000. PYA Waltman Capital LLC purchased a new position in Pfizer in the fourth quarter worth $31,000. Rinkey Investments purchased a new position in Pfizer in the fourth quarter worth $32,000. Finally, Stuart Chaussee & Associates Inc. lifted its stake in shares of Pfizer by 108.3% during the first quarter. Stuart Chaussee & Associates Inc. now owns 625 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 325 shares during the period. 66.50% of the stock is currently owned by institutional investors and hedge funds.

About Pfizer (Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Recommended Stories

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.